Overview

Electroceuticals: Microcurrents as Medicine

With advances in microprocessing, the field of electroceuticals is exploding, and yesterday’s slow-and-seldom breakthroughs have turned into a tsunami of rapid discoveries and new treatments using microcurrent therapy. These new treatments are so much more flexible and powerful that they have caught the attention of mainstream media and a number of major corporations who are developing electroceutical devices of their own.

Microcurrent has gone mainstream. Check out the article below that was featured in the Health & Medicine Section of Time Magazine.

Time Magazine — Highlighting Bioelectric Medicine’s Incredible Potential:

“While some bioelectronic, or electroceutical, therapies already exist to treat conditions such as headaches, certain cases of depression, as well as chronic and sinus pain, the new wave of electricity-based strategies could expand to help people with some of the most widespread chronic diseases in the world, including high blood pressure, arthritis, diabetes, some forms of blindness and even dementia.”
This Technology has Spawned a New Medical Sector with a Fast Growing $35 Billion Market

Grandview Research predicts that electroceutical/bioelectric medicine will be a $35.5 billion market by 2025[i]. Many forward-thinking investors have already taken positions in bioelectric medicine, as the field is still young and has enormous growth potential.  Another sign that bioelectric medicine is on firm footing is the number of major corporations that are entering the sector, below are examples of 4 corporations making strides in bioelectric medicine.

GlaxoSmithKline (GSK), with support from Alphabet, set up Galvani Bioelectronics to work on an implant device that will wrap around a bundle of nerves to treat diseases.

Boston Scientific (BSX) & Medtronic (MDX) – Both companies have a long history in bioelectronics with pacemakers and spinal cord stimulation devices.

Nevro Corp. (NVRO) – Makes pain control devices using spinal cord stimulation (SCS).

Standing out amongst these large corporations is a small company, Cell MedX who have now completed observational clinical trials for the eBalance® device with promising results.

Cell MedX Corp. (CMXC) – completed research and development observational clinical trials for the eBalance® Systems. Health Canada granted Cell MedX (Canada) Corp., the Company’s wholly-owned subsidiary, Class II Medical Device Licenses for both the eBalance® Pro System and eBalance® Home System in 2020. Both microcurrent systems are approved for pain relief and general relaxation.

Microcurrent Leads Electroceutical Therapy

Cell MedX’s eBalance® Technology device delivers microcurrents in specific strengths, frequencies and waveforms through the body in 15 to 30-minute treatments giving flexibility and control to potentially target a range of conditions. The eBalance® Home System and eBalance® Pro System are approved as Class II Medical Device Systems by Health Canada for the treatment of pain and general relaxation. Cell MedX conducted a Health Canada approved clinical observational trial. The results of that study are highlighted below.

Cell MedX — Research and Development

As part of Cell MedX’s commitment to research and development, an R&D observational clinical trial was completed on diabetic subjects using 3 months of eBalance® treatments twice weekly (the “Trial”) with no significant side effects or safety issues. The following R&D results were observed:

Diabetes

After three months of bi-weekly eBalance® treatments, the average fasting blood glucose levels declined by 12.38% and plasma insulin declined by 46.7%. These results indicate that, on average, the blood glucose uptake was increased and that less insulin was required to achieve that uptake. A double-blind, placebo-controlled study in the area of diabetes treatment may be conducted in the future. Note: eBalance® Systems have Health Canada approval as Class II Medical Device Systems for the treatment of pain and general relaxation.

Blood pressure

After 12 weeks of eBalance® treatment, systolic pressure, the amount of pressure in the arteries during the contraction of the heart muscle, declined by 9.6% and diastolic pressure, the lower pressure number in the arteries when the heart muscle is between beats, declined by 10.4%. The Company is planning to undertake further studies on subjects with higher blood pressures to determine if a proportional effect is obtained as has been observed within individuals who have used the eBalance device. A 10% decrease in blood pressure for individuals at risk from high blood pressure could be very beneficial without the side effects of medications.

Pain and numbness

Neuropathy is nerve damage that can occur with diabetes as a result of high blood glucose levels and high blood pressure. The damage most often affects the extremities and causes pain, tingling or numbness in the hands, arms, legs and feet. Only two subjects suffered from pain at the beginning of the Trial and both reported feeling either less pain or reduced coldness or numbness in their extremities. The Company is preparing to conduct further R&D on neuropathy and other forms of chronic pain, such as gout, migraines and inflammation.

Kidney function

Nephropathy is damage caused to the small blood vessels in the kidneys by high blood glucose levels and high blood pressure that prevents them from functioning properly or even causes them to fail completely. When the blood vessels in the kidneys are injured, the kidneys cannot clean the blood properly. The body will retain more water and salt than it should, which can result in weight gain and oedema. In the Trial, there were some indications that eBalance treatments improved kidney function which is supported by individual observations of significant reductions of oedema. A longer study of eBalance® treatment for kidney function is highly desirable.

Cell MedX Corp. (CMXC), fully reporting US-listed company & reporting issuer in Canada

Investing in Cell MedX (CMXC)

Unique Electroceutical Opportunity—Cell MedX offers a pure-play on the fast-evolving field of electroceuticals through eBalance® Technology.

Meaningful Innovation—The eBalance® is approved in Canada for pain & general relaxation. With Cell MedX’s commitment to ongoing R&D, it may prove to be an important breakthrough in chronic disease management in future.

Outstanding Safety— eBalance® Systems have proven safety through observational clinical trials with no harmful side effects.

Easy to Use— eBalance® Systems incorporate advanced state-of-the-art user-friendly interface for ease-of-use.

Pipeline Potential — Outstanding potential for follow-on systems and devices built with the same technology to empower patients to achieve wellness-at-home.

[i] https://www.grandviewresearch.com/press-release/global-electroceuticals-bioelectric-medicine-market

Read More about eBalance® Technology

Company Information

  • Publicly listed: OTCQB: CMXC
  • CUSIP Number: 15115X 107
  • ISIN Number: US15115X1072
  • State of Incorporation: NV
  • Date of Incorporation: March 19, 2010
  • SEC Reporting Status: Compliant
  • Fiscal Year End: May 31
  • Shares Issued and Outstanding: 294,736,373 as of January 4, 2024

View Share Trading Data

Review Regulatory Filings

Read Our Corporate News

Contact Investor Relations

Forward-Looking Statements

The information included here has not been reviewed by Health Canada or the FDA, nor has it been peer-reviewed. This information contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects”, “intends”, “estimates”, “projects”, “anticipates”, “believes”, “could”, and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on the Company’s forward-looking statements. In particular, the Company’s eBalance® technology is still in development. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.


Cell MedX Corp. News Alerts

To receive news alert about Cell MedX, please subscribe with your email address below:

News Alerts

Stay up-to-date on Cell MedX News by subscribing with your email address below:


Cell MedX: Bringing Microcurrent to Market